The weight of obesity in breast cancer progression and metastasis: clinical and molecular perspectives
Publication date: Available online 3 September 2019Source: Seminars in Cancer BiologyAuthor(s): Ines Barone, Cinzia Giordano, Daniela Bonofiglio, Sebastiano Andò, Stefania CatalanoAbstractThe escalating epidemic of overweight and obesity is currently recognized as one of the most significant health and economic concern worldwide. At the present time, over 1.9 billion adults and more than 600 million people can be, respectively, classified as overweight or obese, and numbers will continue to increase in the coming decades. This alarming scenario implies important clinical implications since excessive adiposity can progressively cause and/or exacerbate a wide spectrum of co-morbidities, including type 2 diabetes mellitus, hypertension, cardiovascular disease, and even certain types of cancer, including breast cancer. Indeed, pathological remodelling of white adipose tissue and increased levels of fat-specific cytokines (mainly leptin), as a consequence of the obesity condition, have been associated with several hallmarks of breast cancer, such as sustained proliferative signaling, cellular energetics, inflammation, angiogenesis, activating invasion and metastasis. Different preclinical and clinical data have provided evidence indicating that obesity may worsen the incidence, the severity, and the mortality of breast cancer. In the present review, we will discuss the epidemiological connection between obesity and breast cancer progression and metastasis and we will highli...
Publication date: Available online 11 July 2020Source: European UrologyAuthor(s): Roderick C.N. van den Bergh, Olivier Rouvière, Theodorus van der Kwast, Erik Briers, Thomas Van den Broeck, Philip Cornford, Marcus G. Cumberbatch, Maria De Santis, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Nikolaos Grivas, Jeremy Grummet, Thomas B. Lam, Michael Lardas, Matthew Liew, Lisa Moris, Malcolm D. Mason, Nicolas Mottet, Daniela E. Oprea-Lager
Publication date: Available online 11 July 2020Source: European Journal of Surgical OncologyAuthor(s): Xin Chen, Xingyu Feng, Muqing Wang, Xueqing Yao
Publication date: Available online 10 July 2020Source: Pathology - Research and PracticeAuthor(s): Yiyang Bai, Jia Hou, Xiao Wang, Luying Geng, Xiaohui Jia, Luochengling Xiang, Kejun Nan
CONCLUSIONS: VIS was feasible in clinical routine. Compared to the other evaluated blocks, the VIS for the infragluteal access to the sciatic nerve was rated worst. VIS is found to be worse in obese patients. Further research is needed to evaluate VIS and its suitability for specific questions as for instance anesthetists' learning curves, comparison of different patient populations, ultrasound devices or different nerve blocks. PMID: 32643357 [PubMed - as supplied by publisher]
Publication date: Available online 10 July 2020Source: Gynecologic Oncology ReportsAuthor(s): McKayla J. Riggs, Miranda Lin, Joseph Kim, Prakash Pandalai, Charles Dietrich
Publication date: Available online 11 July 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Federico Boscari, Mario Luca Morieri, Anna Maria Letizia Amato, Valeria Vallone, Ambra Uliana, Anna Baritussio, Nicola Vitturi, Elisa Cipponeri, Francesco Cavallin, Angelo Avogaro, Gian Paolo Fadini, Daniela Bruttomesso
Publication date: Available online 10 July 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Caterina Bonfiglio, Carla Maria Leone, Liciana Vaz de Arruda Silveira, Rocco Guerra, Giovanni Misciagna, Maria Gabriella Caruso, Irene Bruno, Claudia Buongiorno, Angelo Campanella, Vito Maria Bernardo Guerra, Maria Notarnicola, Valentina Deflorio, Isabella Franco, Antonella Bianco, Antonella Mirizzi, Laura Rosana Aballay, Anna Maria Cisternino, Paolo Sorino, Pasqua Letizia Pesole, Alberto Rubén Osella
Publication date: October 2020Source: Journal of Functional Foods, Volume 73Author(s): Christopher M. McLaughlin, Shaun J. Sharkey, Pádraigín Harnedy-Rothwell, Vadivel Parthsarathy, Philip J. Allsopp, Emeir M. McSorley, Richard J. FitzGerald, Finbarr P.M. O'Harte
Publication date: Available online 11 July 2020Source: Medical Journal Armed Forces IndiaAuthor(s): Nikita Naredi, Pankaj Talwar, Sandeep Karunakaran
In this study, 1452 patients were enrolled. Independent risk factors for recurrence-free survival (RFS) and overall survival (OS) were analyzed for patients with and without CSPH. For HCC patients without CSPH, multivariate analysis suggested that microvascular invasion (MVI), neutrophil-to-lymphocyte ratio (NLR) ≥ 3, platelet-to-lymphocyte ratio (PLR) ≥ 150, tumor size> 5 cm, and the presence of a satellite lesion were independently associated with RFS. MVI, NLR ≥ 3, PLR ≥ 150, and advanced Barcelona clinical liver cancer (BCLC) stage contributed to mortality. However, neither NLR nor PLR showed any prognos...